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1. Introduction 
Cardiac arrhythmias are one of the important problems in coronary ischemia/reperfusion 
(I/R) therapy and constitute a major risk for sudden cardiac death after coronary artery 
occlusion (Pourkhalili et al., 2009). Arrhythmias occur in up to 25% of patients treated with 
digitalis, 50% of anesthetized patients, and over 80% of patients with acute myocardial 
infarction (AMI) (Hume & Grant, 2007). Although reperfusion is the only way to restore 
blood flow of coronary arteries and prevent the myocardium from suffering from necrosis, it 
will lead to the occurrence of life-threatening arrhythmias which containing premature 
ventricular beats (PVBs), ventricular tachycardia (VT) and ventricular fibrillation (VF) (Wei 
& Yang, 2006). There are few safe and effective antiarrhythmic drugs for use in patients with 
ischemic heart diseases (IHD). Class I antiarrhythmic agents such as quinidine, flecainide, 
propafenone, and procainamide have the potential to cause proarrhythmia and 
hemodynamic collapse in the setting of IHD and should be used with caution. The use of 
beta-adrenergic receptor blockers and calcium channel blockers such as diltiazem and 
verapamil may be limited by side effects such as heart rate slowing and blood pressure drop 
(Dhalla et al., 2009). Therapeutic strategies currently used for primary prevention of VF, VT, 
or cardiac arrest remain controversial as few trials have shown a survival benefit. In 
addition, sudden cardiac death caused by I/R-induced arrhythmias is a warning to the 
development of new antiarrhythmic agents (Pourkhalili et al., 2009). Pharmacological 
protection of the heart from I/R-induced damage has been investigated by academic and 
industrial scientists for a considerable period of time. A central aim of research directed 
towards the science and pharmacology of I/R injury is the discovery of drugs that can be 
used in human to prevent ischemic cardiac injury and its sequelae (Black, 2000). 
This chapter reviews and describes the pharmacology of some important “metabolic agents” 
that suppress arrhythmias by metabolism modulating in cardiac cells.  
2. Energy metabolism in the aerobic heart 
The high energy demand of the heart is met by utilizing a variety of carbon substrates, 
including free fatty acids (FFAs), carbohydrates, amino acids and ketone bodies. FFAs and 
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carbohydrates are the major substrates from which heart derives most of its energy 
(Sambandam & Lopaschuk, 2003; Calvani et al., 2000). Under normal aerobic conditions, 50–
70% of the total energy is obtained from fatty acids, while the majority of the rest is obtained 
from carbohydrates (mainly glucose and lactate) (Sambandam & Lopaschuk, 2003). The 
carbon substrates are all converted to acetyl coenzyme A (acetyl-CoA) and enter the citric 
acid (Krebs) cycle whereby they produce the high-energy phosphate molecule adenosine 
triphosphate (ATP) which powers both contractile and noncontractile functions (McBride & 
White, 2003). The citric acid cycle also generates the electron accepting molecule 
nicotinamide adenine dinucleotide (NADH), which produces additional ATP molecules by 
interacting with the electron transport chain inside the mitochondria. These 3 
macronutrients possess different metabolic pathways to generate acetyl-CoA molecules. 
Glycogen is converted to glucose, which is then converted to pyruvate in the cytoplasm. 
Pyruvate enters the mitochondria and is converted to acetyl-CoA by pyruvate 
dehydrogenase (PDH). Conversely, fatty acids are converted to fatty acyl-CoA and then 
undergo several metabolic steps before being converted to acetyl-CoA by the ǃ-oxidation 
pathway. The principal difference between the 2 pathways of energy production is the 
amount of oxygen required to produce a given amount of ATP. With fatty acid oxidation, 32 
grams of oxygen will yield 5.5 ATP molecules while glucose oxidation produces 6.3 
molecules of ATP (McBride & White, 2003). The rate of fatty acid oxidation is mainly 
regulated by the concentration of free fatty acids in the plasma, the activity of carnitine 
palmitoyl transferase-I (CPT-I), and the activity of a series of enzymes that catalyze the 
multiple steps of fatty acid ǃ-oxidation. Fatty acid oxidation strongly inhibits glucose and 
lactate oxidation at the level of PDH (Sabbah & Stanley, 2002). 
3. Myocardial ischemia and reperfusion injury 
Myocardial ischemia is one of the major causes of death in nowadays cardiac diseases (Wei 
& Yang, 2006). Among the heart diseases, I/R-induced arrhythmias contribute to episodes 
of sudden death (Gandhi et al., 2009). Reperfusion of myocardium subjected to a transient 
ischemia rapidly induces ventricular arrhythmias including PVBs, VT and VF in both 
animals and human (Lu et al., 1999).  
3.1 Myocardial function and energy production during ischemia  
Myocardial ischemia is a condition that exists when there is a reduced coronary blood flow, 
and results in a decrease in the supply of oxygen and nutrients to the heart (Suleiman et al., 
2001). Due to restricted oxygen supply to the myocardium during ischemic period, both 
fatty acid and carbohydrate oxidation decreases and ATP production is impaired. 
Glycolysis, a minor source of ATP in the aerobic heart, becomes a more significant source of 
energy during ischemia. In the severely ischemic myocardium, production of H+ from 
hydrolysis of glycolytically derived ATP is the major contributor to acidosis (Sambandam & 
Lopaschuk, 2003; Suleiman et al., 2001; Calvani et al., 2000). In particular, lactic acid 
accumulates, leading to an increase in intracellular Na+ and Ca2+ (Suleiman et al., 2001). The 
accumulation of fatty acids and their intermediates during myocardial ischemia as well as 
metabolic and ionic changes provoke a reduction of myocardial function and also have been 
shown to be deleterious to the recovery of myocardial function of the reperfused heart 
(Ford, 2002).  
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3.2 Myocardial function and energy production during reperfusion 
Functional recovery upon reperfusion is largely dependent upon the duration of the 
ischemic period; the longer the period, the more likely the heart is to undergo irreversible 
damage. Consequences of reperfusion injury include cardiac arrhythmias, myocardial 
stunning and loss of intracellular proteins (Suleiman et al., 2001). Numerous mechanisms for 
the increase in tissue injury after reperfusion have been proposed including oxidative stress 
(Gandhi et al., 2009), the generation of oxygen-derived free radicals (Wei & Yang, 2006), 
calcium overload (Wei & Yang, 2006; Lu et al., 1999), and dysfunction of myocardial energy 
metabolism (Wei & Yang, 2006). 
4. Metabolic pharmacology 
As mentioned previously, the myocardium preferentially uses fatty acids for an energy 
source because the chemical bonds of fatty acid molecules have higher energy content and 
are capable of producing more ATP molecules per molecule of fatty acid consumed. Since 
the inhibition of ǃ-oxidation could permit the heart to produce ATP at lower oxygen 
tensions, it is plausible that an inhibitor of ǃ-oxidation could prevent damage to the 
myocardium when subjected to ischemia (McBride & White, 2003). The principal goal of the 
metabolic modulator approach is to decrease the rate of fatty acid oxidation by the heart and 
increase the oxidation of pyruvate derived from glucose, glycogen, and lactate (McCormack 
et al., 1998). Switching the source of acetyl CoA from fatty acids toward pyruvate results in: 
greater ATP yield and amelioration of the buildup of potentially harmful fatty acid 
metabolites, and should also act to decrease lactate and hydrogen ion production under low 
flow conditions and during postischemic reperfusion (McCormack et al., 1998).  
5. Pharmacology of some important metabolism modifiers 
5.1 L-carnitine (L-Car) 
5.1.1 Structure 
Carnitine, a name derived from the Latin caro or carnis (flesh), was discovered in muscle 
extracts in 1905. Soon after, the chemical formula C7H15NO3 was accepted, and in 1927, its 
structure, a trimethylbetaine of Ǆ-amino-ǃ-hydroxybutyric acid, was identified and 
published (Fig 1). In 1962, the configuration of the physiological enantiomer was 
determined, and in 1997 confirmed as L(-) or R-(-)-3-hydroxy-4-N,N,N-
trimethylaminobutyrate (Sweetman, 2002; Kerner and Hoppel, 1998; Rebouche and Seim, 
1998). 
 
Fig. 1. Chemical structure of carnitine. 
5.1.2 Pharmacokinetics 
Oral doses of L-Car are absorbed slowly and incompletely from the small intestine via a 
stereoselective active transport system located in the intestinal mucosa of the duodenum 
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and ileum (Sweetman, 2002). L-Car transport does not appear to occur below the ileum in 
the large intestine. The transport system can concentrate L-Car, resulting in a 10 to 100 fold 
gradient between the extracellular and intracellular compartments. Additionally, a passive 
diffusion of L-Car has also been demonstrated in the intestine. Peak plasma levels of free 
and total carnitine occurs 3-5 hours after oral administration. The normal total plasma 
carnitine concentrations for healthy men and women are 59 μmol/L and 51 μmol/L, 
respectively (Bach et al., 1983). It does not appear to bind to plasma proteins (Rebouche, 
2004; Sweetman, 2002). The plasma half-life of L-Car has been estimated to range from 2-15 
h in humans. Although carnitine is largely eliminated via renal excretion, it is highly 
conserved by the kidney. L-Car is freely filtered at the renal glomerulus and greater than 90 
percent of the filtered load is reabsorbed in the proximal kidney tubules and returned to the 
circulation when plasma carnitine levels are normal or low. L-Car given orally may undergo 
degradation in the gastrointestinal tract, leading to the formation of metabolites such as 
trimethylamine-N-oxide and Ǆ-butyrobetaine (Sweetman, 2002). 
5.1.3 Pharmacodynamics 
L-Car facilitates oxidation of long-chain fatty acids (LCFAs) and is involved in trapping acyl 
residues from peroxisomes and mitochondria. It participates in metabolism of branched 
chain amino acids (Lango et al., 2001). Supplementation of the myocardium with L-Car 
results in an increased tissue carnitine content which restores carnitine losses and lessens the 
severity of ischemic injury. It also improves the recovery of heart functions during 
reperfusion. The beneficial effects of L-Car on heart function recovery from ischemia cannot 
be justified by this drug stimulating fatty acid oxidation only. Fatty acids, high in plasma 
during reperfusion, may provide 90 % of ATP production in the absence of L-Car treatment, 
whereas in its presence a marked increase in glucose oxidation is observed, without changes 
in total ATP production. Thus, these results suggest that the drug tends to restore the 
balance between fatty acid and glucose oxidation. L-Car is thought to increase glucose 
oxidation by relieving PDH inhibition caused by the elevated intramitochondrial acetyl-
CoA/CoA ratio. This effect also results in an increased synthesis of malonyl-CoA, the 
physiological inhibitor of CPT-1, the first committed enzyme in overall fatty acid oxidation. 
Increased glucose oxidation is beneficial for cardiac cells because of a lower conversion of 
pyruvate into lactate, a metabolic step contributing to acidification of the intracellular 
compartment. Finally, L-Car have been proposed to mitigate the noxious effects of oxygen 
free radicals in the reperfused hearts and to render cardiac cells more resistant to I/R 
damage by stabilizing cellular membranes (Lango et al., 2001, Calvani et al., 2000). 
5.1.4 Uses of L-Car in cardiovascular health and diseases 
A decreased carnitine concentration in the heart was observed in patients who died of 
myocardial infarction (MI). In patients with AMI, a four fold increase was observed in free 
carnitine elimination and almost a two-fold increase in the elimination of short chain 
carnitine esters by kidney (Lango et al., 2001). There is some evidence that L-Car 
supplementation may exert a cardioprotective role. Benefit in patients with 
cardiomyopathies,reduction of infarct size and prevention of arrhythmias in patients with 
MI,increased exercise tolerance in patients with angina,and protection from the 
cardiotoxicity of the anthracycline antineoplastics have all been described in patients given 
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L-Car supplementation (Lango et al., 2001). Arsenian et al. demonstrated a decrease in 
mortality and incidence of circulatory failure in a group of patients with AMI, who were 
administered 3 g of L-Car along with solution of glucose, insulin, potassium and 
magnesium (Arsenian et al., 1996). L-Car supplementation in patients with congestive heart 
failure (CHF) for 12 weeks significantly improved the exercise tolerance of patients with 
effort angina. Studies involving about 2500 patients with coronary artery disease (CAD) 
treated with L-Car for a year also showed a reduced incidence of angina, a decreased need 
of cardiac drugs and a greater effort tolerance (Naguib, 2005). Placebo-controlled studies 
performed in patients with stable chronic effort angina suggest that L-Car given acutely (40 
mg/kg, iv) or chronically (1–3 g daily for a month) improves exercise capacity and the 
electrocardiographic manifestations of ischemia (Ferrari et al., 2004). L-Car does not have 
hemodynamic effects in healthy volunteers or patients with CAD. However, an 
improvement of individual maximal aerobic power is demonstrated in healthy subjects and 
athletes after chronic treatment with L-Car (4 g daily over a period of 2 weeks) (Ferrari et al., 
2004). In a randomized, double-blind, placebo controlled, multicenter study called the 
Levocarnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial was 
performed to evaluate the effects of L-Car administration on long-term left ventricular 
dilatation in patients with AMI. Placebo or levocarnitine (9 g iv daily for the first 5 days and 
then 6 g orally daily) was administered for 12 months. The primary end points of the trial 
were left ventricular volumes and ejection fraction, at 12 months after the emergent event, 
assessed by two-dimensional echocardiography. Treatment with the active compound 
resulted in a significant reduction of left ventricular dilatation. The percentages of both end-
diastolic and end-systolic volumes were reduced significantly in the L-Car-treated group. 
No modification of left ventricular ejection fraction was observed. The incidences of death, 
congestive heart failure, and/or ischemic events were less in the L-Car-treated groups 
(Ferrari et al., 2004). Administration of L-Car, combined with other treatments, also proved 
effective in the treatment of childhood cardiomyopathy (Szewczyk and Wojtczac, 2002). 
Oral L-Car (3–4 g daily) normalizes plasma total cholesterol or triglyceride levels (or both) 
and increases high-density lipoprotein (HDL)–cholesterol in patients with type II and type 
IV hyperlipoproteinemia over a 2-month period (Ferrari et al., 2004). Oral L-Car (4 g daily 
for 21 days) improves the maximal walking distance of patients with intermittent 
claudication caused by peripheral arterial disease (Ferrari et al., 2004). Decreased level of 
free and total carnitine in diabetes, with a simultaneous increase in concentrations of long-
chained acyl-CoA and long-chain carnitine esters has been shown. Some correlation has 
been also demonstrated between the left ventricular contraction index and long-chain acyl- 
carnitine concentration in the myocardium during reperfusion in patients after mitral valve 
replacement. These data suggest, in line with the results of experimental studies that 
carnitine and its derivatives protect human ischemic heart against oxidative stress not only 
by modifying carnitine acyl-transferase activity and metabolic effect, but by other 
mechanisms as well (Lango et al., 2001). 
5.1.5 Experimental and clinical findings on beneficial effects of L-Car against cardiac 
arrhythmias 
A prolonged L-Car therapy in patients with angina pectoris was associated with a 
considerable decrease in the frequency of ventricular arrhythmias (Lango et al., 2001). 
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Rizzon et al. noticed a statistically significant decrease of the frequency of ventricular 
arrhythmia in a group of patients with AMI who were administered 100 mg of L-Car/kg. 
Although the studied groups of patients were small, L-Car administration to patients with 
ischemic heart disease appears to be a promising therapy of ischemia-induced arrhythmia as 
potentially addressed to restoring of membrane rest-potential (Rizzon et al., 1989). Cardiac 
electrophysiology after L-Car administration (30 mg/kg over 3 min) did not show any 
changes either in the conductivity time or in refraction period. The cycle duration in the 
sinus node was shortened by 5%, while the arterial blood pressure remained unchanged 
(Lango et al., 2001). Results of some experimental studies showed protective effects of L-Car 
against I/R- induced injuries and cardiac arrhythmias. In a study, we tested the effects of 
0.5, 2.5 and 5 mM/L of L-Car on cardiac arrhythmias in the ischemic reperfused isolated rat 
heart in Langendorff setup. At the ischemic phase, number, duration and incidence of VT 
were decreased by doses of 2.5 and 5 mM/L L-Car (p<0.05). In addition, L-Car by doses of 
2.5 and 5 mM/L reduced the number of VT (p<0.05) at the reperfusion phase. The total 
number of ventricular ectopic beats (VEBs: Single+Salvos+VT) also were reduced in treated 
groups by 0.5-5 mM/L of L-Car versus the control group (p<0.05). However, duration of 
reversible VF (Rev VF) was decreased only by 5 mM/L L-Car (Najafi et al., 2005). In another 
study, the effects of pre-ischemic administration of 0.5, 2.5 and 5 mM/L of L-Car were 
investigated in isolated rat hearts. Interestingly, the results showed that short time pre-
ischemic administration of L-Car (10 min before induction of 30 min regional ischemia) had 
concentration dependent arrhythmogenic effects on both ischemia and reperfusion-induced 
arrhythmias (Najafi et al., 2008). The authors hypothesized that pre-ischemic using of L-Car 
for an inadequate time can be harmful for the heart because of incomplete metabolism of 
fatty acids and more accumulation of their intermediates (Najafi et al., 2008). They 
concluded that L-Car produced a protective effect against reperfusion arrhythmias only 
when it is perfused for the whole period of the experiment. This protective action was 
reversed by concomitant using of etomoxir (palmitoylcarnitinetransferase-1 inhibitor), 
suggesting that the efficacy of L-Car is due to its mitochondrial action, but is probably not 
solely attribute to an increase in fatty acid oxidation (Najafi et al., 2008). Cui et al. 
investigated the effects of L-Car on the incidence of reperfusion-induced VF during 30 min 
global ischemia followed by 120 min reperfusion. Their results showed that different 
concentrations of L-Car failed to reduce the incidence of VF (Cui et al., 2003). Suzuki et al. 
reported intravenous pre-treatment of the ischemic dog heart by L-Car (100 mg/kg) reduced 
the grade of ventricular arrhythmias. They suggested that the administration of L-Car might 
be beneficial to prevent serious arrhythmias in ischemic heart disease, presumably by 
restoring the impaired free fatty acid oxidation (Suzuki et al., 1981). Recently, we reported 
that pre-ischemic administration of L-Car could precondition the heart as evidenced by its 
ability to lower the infarct size markedly (p<0.001) and improved postischemic ventricular 
functional recovery. L-Car reduced left ventricular end diastolic pressure (LVEDP) elevation 
at the reperfusion phase. Heart rate (HR) and coronary flow rate (CFR) did not show 
significant changes in treated groups as compared to the control. Among the three different 
concentrations, L-Car (2.5 mM) was found to be optimal for preconditioning purpose (Najafi 
et al., 2010a). It was also found in this study that pre-ischemic administration of L-Car in 
ischemic/reperfused hearts preconditions the hearts by reduction of left ventricular lactate 
content (Najafi et al., 2010a). 
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5.1.6 Uses of L-Car in other human diseases 
As well as cardiovascular health and diseases, L-Car is administered to treat many other 
human diseases such as primary carnitine deficiency syndromes or secondary carnitine 
deficiency/insufficiency states (Ferrari et al., 2004). Primary carnitine deficiency results from 
inborn defects in specific proteins or carnitine transferases. Therapy with carnitine in 
primary deficiency states is considered to have a rational basis. Secondary causes of 
carnitine deficiency include inherited metabolic defects in fatty acid ǃ-oxidation, 
mitochondrial myopathy, prematurity, carnitine deficiency in the diet, dialysis therapy, etc. 
The value of carnitine for these conditions is controversial (Sweetman, 2002; Szewczyk et al. 
2002; Kerner & Hoppel, 1998).  
5.1.6.1 Infant nutrition 
Preterm infants require carnitine for life-sustaining metabolic processes. When infants were 
supplemented with 2.2 mg of L-Car/100 ml in the bovine milk formula, their plasma 
carnitine and acylcarnitine levels were similar to those observed in the breast-fed group 
(Naguib, 2005). 
5.1.6.2 Immune system and AIDS  
The effect of long-term L-Car supplementation on CD4 and CD8 absolute counts, rate, and 
apoptosis was studied in HIV-infected subjects, who were treated with daily infusions of L-
Car (6 g) for 4 months. CD4 and CD8 are specific types of lymphocytes; their absolute 
counts are decreased in patients with AIDS, resulting in compromised immune function. At 
the end of the study, L-Car was found to substantially increase the rate and absolute counts 
of CD4 and, to a lesser degree, of CD8 lymphocytes (Ilias et al., 2004; De Simone & 
Tzantzoglou, 1993). In this case, the antioxidant activity of L-Car may be responsible for the 
observed changes in apoptosis because increases in free radical oxidative stress can 
accelerate this process (Moretti et al., 1998). 
5.1.6.3 Brain health 
L-Car has been considered of potential use in senile dementia of Alzheimer's because of its 
ability to enhance energy production and to restore aged cell membranes (Naguib, 2005). In 
brain tissue, the carnitine shuttle mediates translocation of the acetyl moiety from 
mitochondria into the cytosol and thus probably contributes to the synthesis of acetylcholine 
(Szewczyk & Wojtczac, 2002). Positive clinical effects of L-Car administration were also 
observed in brain ischemia (Lango et al., 2001) and hypoglycemia induced by insulin 
overdose (Hino K. et al. 2005). In addition, L-Car protects motor neuron cells from ischemic 
spinal cord injury (Akgun et al., 2004). 
5.1.6.4 Physical performance 
In addition to enhancing ǃ-oxidation of LCFAs in skeletal muscle, L-Car may also benefit 
exercise performance by decreasing muscle glycogen depletion, shifting energy sources to 
the highly efficient aerobic glucose metabolic pathways, replacing decreased L-Car that has 
shifted to acylcarnitine during exercise, lowering content of toxic acyl groups and increasing 
of muscle blood flow secondary to vasodilation (Lango et al., 2001; Brass, 2000). Beneficial 
effect of L-Car in healthy subjects in an attempt to improve athletic performance is 
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controversial (Sweetman, 2002). However, it is used as legal dope in sports (Szewczyk & 
Wojtczac, 2002). 
5.1.6.5 Other uses 
L-Car treatment significantly improved symptoms in chronic fatigue syndrome (CFS) 
patients without side effects (Naguib, 2005). There is some suggestion that L-Car 
supplementation may be benefit in alleviating chemotherapy-induced fatigue (Sweetman, 
2002). L-Car supplementation has been approved by the FDA not only for the treatment but 
also for the prevention of carnitine depletion in dialysis patients. Regular L-Car 
supplementation in hemodialysis patients can improve their lipid metabolism, protein 
nutrition, antioxidant status and anemia requiring large doses of erythropoietin. It also may 
reduce the incidence of intradialytic muscle cramps, hypotension, asthenia, muscle 
weakness and cardiomyopathy (Bellinghieri et al., 2003). Chronic hemodialysis produces 
cardiac damage caused by anemia, hypertension and overhydration. L-Car in a long-term 
supplementation has been shown to be beneficial to the function of erythrocytes in 
hemodialysed patients. Additionally, supplementing improves measures of vitality and 
overall self-perceptions of general health and quality of life in hemodialysed patients and 
the typical dialysis-associated muscle symptoms (Lango et al., 2001; Kazmi et al., 2005). 
Sodium valproate is a commonly used as an antiepileptic agent that has been reported to 
inhibit the biosynthesis of carnitine (Farkas et al., 1996) and reduce carnitine plasma 
concentrations via its ability to bind L-Car. Researchers have suggested that the incidence of 
idiosyncratic fatal hepatotoxicity caused by sodium valproate results from impaired ǃ-
oxidation of fatty acids in the liver. Valproate has also been shown to impair the tissue 
uptake of carnitine. Ataxia, hyperammonemia, lethargy, nausea and stupor characterize 
both carnitine deficiency and sodium valproate hepatic toxicity. In 1996, the pediatric 
neurology advisory committee recommended supplemental L-Car for younger patients who 
are taking sodium valproate, carbamazepine, phenytoin or phenobarbital. In addition, L-Car 
(i.v.) is considered as a treatment of choice to prevent potentially fatal liver dysfunction 
associated with valproate overdose (LoVecchio et al., 2005; Lango et al., 2001). L-Car 
alleviates the cardiotoxic effect of adriamycin. Adriamycin is highly toxic to nonmalignant 
tissues due to the generation of reactive oxygen species (ROS) (Szewczyk & Wojtczac, 2002). 
In diabetes, L-Car supplementation causes a decrease in triglyceride synthesis, a drop in the 
cellular free fatty acids (FFAs) uptake, and the removal from organism of excessive long-
chain carnitine esters, as well as increase in glycolysis, oxidation of pyruvate, and 
improvement in neuronal transmission (Mingrone, 2004; Lango et al., 2001). Moreover, 
protective effects of L-Car against I/R-induced apoptosis were shown by 
immunohistochemical detection method in rat cardiomyocytes (Najafi et al., 2007). 
5.1.7 Adverse effects of L-Car 
Gastrointestinal disturbances such as nausea, vomiting, diarrhea, abdominal cramps 
(Sweetman, 2002), heart-burn, dyspepsia, seizures, blurred vision and headache (Lango et 
al., 2001) have been reported following the administration of L-Car. Unpleasant body odor 
that is similar to that of rotten fish has also been noticed in some patients (fish odour 
syndrome), possibly due to the formation of the metabolite trimethylamine (Lango et al., 
2001). There are no reports to date of serious side effects caused by L-Car (Sweetman, 2002; 
Lango et al., 2001). Patients with severe renal impairment should not be given high orally 
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doses of L-Car for long periods, because of the accumulation of the metabolites 
trimethylamine and trimethylamine-N-oxide. Diabetic patients administered carnitine while 
receiving insulin or hypoglycemic drugs should be monitored for hypoglycemia (Sweetman, 
2002). 
5.2 Acetyl-L-carnitine (ALC) 
ALC belongs neither to the vitamin nor the amino acid category. It is chemically similar to 
carnitine, but is more efficient. While it is synthesized by the liver from lysine and 
methionine, adequate amounts of vitamins C, B3, and B6, plus iron, lysine, and methionine 
are needed in the diet for this to occur (David, 2000). It is also synthesized in the human 
brain and kidney by the enzyme ALC transferase (Furlong, 1996). Its main body stores are 
skeletal and cardiac muscles. It is found along with free plasma carnitine and other acyl-
esters of varying chain length (Goa & Brogden, 1987). 
5.2.1 Structure of ALC 
ALC is an ester of the trimethylated amino acid, L-carnitine (David, 2000) with following 
structure (molecular formula: C9H17NO4HCl) (Budavari, 2001) 
 
Fig. 2. Chemical structure of ALC. HCl.  
5.2.2 Pharmacokinetics of ALC 
ALC is administered orally or intravenously and is then absorbed in the jejunum by simple 
diffusion (Marcus & Coulston, 1996; Parnetti et al., 1992). Bioavailability of ALC is thought 
to be higher than L-Car. The results of in vitro experiments suggest that ALC is partially 
hydrolyzed upon intestinal absorption (Gross et al., 1986). Both IV and oral administration 
result in a corresponding increase in cerebrospinal fluid (CSF) concentrations of ALC, 
indicating it readily crosses the blood-brain barrier. ALC undergoes little metabolism and is 
subsequently excreted in the urine via renal tubular reabsorption (Marcus & Coulston, 1996; 
Parnetti et al., 1992). Though ALC is an ester of the L-Car, nutritional carnitine deficiencies 
have not been identified in healthy people without metabolic disorders, suggesting that 
most people can synthesize enough L-Car (Rebouche et al., 2006). Even strict vegetarians 
show no signs of carnitine deficiency, despite the fact that most dietary carnitine is derived 
from animal sources (Lombard et al., 1989). 
5.2.3 Mechanism of action of ALC 
ALC is an ester of carnitine and plays a fundamental role in normal mitochondrial function, 
being a transport molecule for free fatty acids and an important acetyl group donor in high 
energy metabolism and free fatty acid ǃ-oxidation (Malaguarnera et al., 2008; Bremer, 1990; 
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Colucci & Gandour, 1988). Results of some studies show that ALC stabilizes the inner 
mitochondrial membrane and reverses the decline in activity of a number of mitochondrial 
translocases and of cytochrome c oxidase thus maintaining energy levels of the cells and 
stabilizing mitochondrial translocase activity (Qureshi et al., 1998; Paradies et al., 1994). ALC 
is known to have antioxidant effects by increasing intracellular coenzyme Q10 levels, which 
accounts for the increase in glutathione reductase activity and high levels of reduced 
glutathione. The augmentation in antioxidant defense system by ALC finally leads to 
quenching of free radicals and reduction in reactive oxygen species and lipid peroxidation 
(Barhwala et al., 2007). ALC could inhibit oxidant-induced DNA single-strand breaks in 
human peripheral blood lymphocytes (Liu et al., 2004). 
5.2.4 Uses of ALC in cardiovascular health and diseases 
Like L-Car, ALC enhances fatty acid transport for ATP production in the mitochondria of 
both skeletal and heart muscles, thereby affording protection from free radical damage 
(Furlong, 1996; Di Giacomo et al., 1993). Additionally, it may improve cardiolipin levels in 
the aged heart, a substance which maintains crucial membrane factors in cardiac 
mitochondria and thus ensures efficient phosphate transport for energy. In a rat 
mitochondrial model, it was shown that ALC administered to aged animals returned 
cardiolipin levels to that of young ones (Paradies et al., 1999; Furlong, 1996). Cerebral and 
peripheral circulation are apparently affected differently by administration of ALC. Ten 
patients with recent cerebral vascular accidents were given ALC intravenously which 
resulted in acute enhancement of cerebral blood flow to areas of ischemia via sensitive 
tomography assessments. In evaluation of patients with peripheral arterial occlusive 
disease, two studies show that the effect of carnitine esters on improved walking distance 
was due to metabolic vs. hemodynamic changes and that Propionyl L-carnitine (PLC) was 
clearly superior to L-Car in this effect. These studies demonstrate the ability of carnitine 
esters to positively influence tissue energetics which may prove beneficial in a chronic 
administration model (Paradies et al., 1999; Furlong, 1996). 
5.2.5 Findings on beneficial effects of ALC against cardiac arrhythmias 
In an experimental study, we focused on the pharmacological effects of ALC on I/R- 
induced cardiac arrhythmias and infarct size in isolated rat heart when it was used during 
30 min regional ischemia followed by 30 min reperfusion. The results of this study showed 
that ALC produces antiarrhythmic effects against regional I/R-induced arrhythmias such as 
VEBs, VT and VF. Perfusion of ALC produced significant reduction in the number of VEBs, 
number and duration of ischemic VT, and duration and incidence of reversible VF by 0.375, 
0.75 and 1.5 mM (p<0.05 for all) and total VF in ischemia time with mentioned 
concentrations (p<0.05). At the reperfusion phase, number of VT and VEBs were decreased 
by all concentrations of ALC, but they weren't statistically significant. In addition, VT 
duration and incidence of total VF were significantly lowered by 0.375, 1.5 and 3 mM of 
ALC (p<0.05). Our findings also demonstrated that ALC caused marked and potent 
protective activity against I/R injuries as reduction of infarct size in this model of study 
(Najafi et al., 2010b). In another study, Cui et al. investigated the effects of ALC on incidence 
of reperfusion-induced VF and infarct size after 30 min global ischemia in isolated rat heart. 
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Their results showed that perfusion of 0.5 and 5 mM of ALC for 10 min before the induction 
of global ischemia (not regional ischemia) failed to reduce the incidence of VF. Their results 
also demonstrated significant reduction in infarct size only by the concentration of 5 mM 
ALC (Cui et al., 2003). Our results are consistent with the results of Cui et al. in the case of 
infarct size reduction quality only. However, in contrast to their results, all the used 
concentrations of ALC in our model significantly reduced infarct size even the lowest 
concentration (0.375 mM). In addition, our results showed that ALC not only lowered VF 
incidence in reperfusion time, but also decreased the number and duration of VT, number of 
VEBs, duration and incidence of total VF in both ischemia and reperfusion time, and 
incidence of reversible VF in both ischemia and reperfusion phase, when it was used 
throughout I/R. We suggested that the existence of some methodological differences 
between the above studies (i.e. type of ischemia and duration of ALC perfusion into the 
heart) caused different results by low concentrations of ALC. However, other studies, such 
as the work done by Rosenthal et al (2005), have also demonstrated the same differences that 
ALC does not promote clinically measurable neuroprotection if administration is 
significantly delayed following restoration of spontaneous circulation. Thus, in order to 
maximize the chances of effective neuroprotection, they postulate that for optimal 
neuroprotective benefit, ALC should be administered as shortly as possible following 
resuscitation, most definitely within 30 min of reperfusion (Rosenthal et al., 2005). It seems 
that the potential cardioprotective mechanisms of action of ALC are very similar to those of 
L-Car (the parent compound of ALC). 
5.2.6 Uses of ALC in other diseases 
5.2.6.1 Cerebral metabolism 
ALC can cross the blood–brain barrier through the Ǆ-amino butyric acid (GABA) uptake 
system (Burlina et al., 1989). In studies on short-term treatment with ALC in aged rats, the 
molecule was found to improve some behavioural and biochemical parameters and 
normalize the age-related impairment in membrane phospholipids metabolism (Aureli et 
al., 1990), and shown to reduce the sphingomyelin and cholesterol accumulation in the aged 
rat brain (Aureli et al., 1994a). ALC treatment was also reported to enhance brain energy 
metabolism and to decrease lactate levels following transient cerebral ischemia (Aureli et al 
1994b). In addition, ALC is involved in acetyl group trafficking among different intracellular 
compartments, and to be a precursor of different lipogenic acetyl CoA pools in rat brain 
(Ricciolini et al., 1997). Studies on the effects of ALC on cerebral metabolism reported a 
significant increase in brain phosphocreatine levels, which was associated with a reduction 
in tissue content of lactic acid and inorganic phosphate (Aureli et al., 1990). ALC 
administration immediately after 20 min of severe cerebral ischemia has also been 
demonstrated to induce a faster recovery of cerebral ATP and a strong decrease in tissue 
lactic acid levels during early post-ischemic reperfusion in the rat (Aureli et al., 1994b). The 
reduction in cerebral glucose oxidative metabolism associated with the increase in newly 
synthesized glycogen, suggests that treatment with ALC may modulate cerebral substrate 
oxidation. Researches showed that the relative flux through pyruvate carboxylase and 
pyruvate dehydrogenase pathways was not affected by ALC. These findings appear to 
suggest an overall metabolic effect of ALC on both neurons and glial cells (Tommaso et al., 
1998). 
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5.2.6.2 Aging processes and Alzheimer’s dementia 
ALC was reported to ameliorate the spatial memory performance of rats exposed to 
neonatal anoxia (Dell et al., 1997) and improvement of spatial memory. In aged rats it could 
be achieved only in intermediate but not in good or poor classes of spatial learning 
performance (Taglialatela et al., 1996). Data shows that improvement could be achieved for 
novel but not for familiar environments (Caprioli et al., 1995). In the Alzheimer's disease 
(AD), brain is under extensive oxidative stress and evidenced by significant protein 
oxidation, lipid peroxidation, and DNA oxidation and is characterized by deposition of 
amyloid ǃ (Aǃ) peptide (Butterfield et al., 2003). Aǃ induces lipid peroxidation in ways that 
are inhibited by free radical antioxidants (Butterfield & Lauderback, 2002). ALC improves 
neuronal energetic and repair mechanism, decreases the level of lipid peroxidation in the 
aged rat brain (Kaur et al., 2001), is involved in mitochondrial metabolism (Hagen et 
al.,1998), and may have antioxidant properties (Poon HF at al., 2006; Kaur J et al., 2001). 
However, the precise mechanism of action by which ALC may be neuroprotective in aging 
and neurodegeneration, is not known. 
5.2.6.3 Chemotherapy-evoked neuropathic pain 
Neurotoxicity is the dose-limiting side effect for chemotherapeutics in the taxane and vinca 
alkaloid classes, and in many cases the nerve damage is accompanied by a chronic painful 
peripheral neuropathy (Cata et al., 2006; Dougherty et al., 2004). Impaired mitochondrial 
function suggests that there might be an energy deficit that compromises the neuron’s 
ability to operate ion transporters. This would lead to membrane depolarization and the 
generation of spontaneous action potentials. Recent evidence suggests that treatment with 
ALC, an agent known to ameliorate mitochondrial dysfunction (Virmani et al., 2005; Zanelli 
et al., 2005), prevents and reverses chemotherapy-evoked pain in rats (Flatters & Bennett GJ, 
2006; Ghirardi et al., 2005a, b). 
5.2.6.4 Diabetic neuropathy 
Studies show that prevention and correction of the metabolic, functional, and structural 
abnormalities characterizing the neuropathy in the diabetic rat after ALC administration. In 
addition, the same treatment showed a promoting effect on suppressed nerve fiber 
regeneration in diabetic rats. In addition, ALC treatment appears to have a sustained 
beneficial effect on vasoactive prostanoid analogues, possibly counteracting the deleterious 
effects of decreased endoneurial blood flow in diabetic nerve (Sima et al., 1996). 
5.2.6.5 HIV infection 
HIV-infected patients on nucleoside analogue therapy commonly experience peripheral 
neuropathy as an adverse effect of the medications. Patients taking stavudine, zalcitabine or 
didanosine may have to discontinue therapy as a result. Some studies have suggested ALC 
as well as recombinant human nerve growth factor may be beneficial in managing this 
condition (Moyle & Sadler, 1998). 
5.2.6.6 Fatigue 
Patients with chronic fatigue syndrome show reduced exercise tolerance, and post exercise 
fatigue induced by minimal physical activity, suggesting decreased muscle function, is 
considered as one of the causes of this syndrome (Jones et al., 2005). Abnormal mitochondria 
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have been observed in muscle of some elderly patients with fatigue, suggesting some 
underlying abnormalities in muscle mitochondrial energy production (Behan et al., 1991). 
The ALC treatment reduced significantly both physical and mental fatigue and improved 
physical activity and cognitive status (Malaguarnera et al., 2007). The improvement of 
energetic metabolism in myocardial tissue and in muscular-skeletal tissue is probably the 
factor that reduces the presence and the severity of physical fatigue in treated subjects. Also 
researches show that ALC is better tolerated and more effective than amantadine for the 
treatment of multiple sclerosis-related fatigue (Tomassini  et al., 2004). 
5.2.6.7 Immune enhancement 
ALC has been found to be a powerful immune enhancer. This is due to its ability to promote 
the health of the nervous system, which in turn governs the activity of the immune system 
(Scarpini et al., 1997). 
5.2.6.8 Effect on cataract 
Cataract accounts for most cases of treatable blindness worldwide. Hence, it is important to 
identify factors that contribute to cataractogenesis with a view to developing novel 
therapeutic and preventive strategies. It has previously shown that ALC exhibits 
anticataractogenic activity in an in vitro and in vivo model of selenite cataractogenesis by 
maintaining antioxidant enzymes at near normal levels and by controlling lipid 
peroxidation (Geraldine et al., 2006). These observations suggest a novel use for ALC as a 
possible cataract-preventing drug (Elanchezhian et al., 2009). 
5.2.6.9 Male infertility 
L-Car and ALC are highly concentrated in the epididymis and are important for sperm 
metabolism and maturation. In a double-blind, cross over trial of 100 infertile patients, 
receiving either L-Car or placebo, a significant improvement in sperm quality was observed 
in the L-Car group. In addition, combination therapy with both L-Car and ALC was given to 
60 infertile men and similar outcomes were observed (Movassaghi & Turek, 2008). 
5.2.7 Adverse effects of ALC 
ALC may cause gastrointestinal disorders and a change in body odor, which can be reduced 
or eliminated with lower dosages. Less frequent side effects include diarrhea, abdominal 
pain, nausea, and vomiting (David et al., 2000). ALC may interfere with thyroid metabolism. 
In individuals with seizure disorders, an increase in seizure frequency and severity has also 
been reported. ALC also increase agitation in some Alzheimer's disease patients (Hendler & 
Rorvik, 2001). Overdosing can produce severe muscle weakness, though some have 
experienced only mild diarrhea with doses as high as 26,000 mg /day (David et al., 2000). 
With long-term (one year) administration, the most common adverse reactions noted have 
been agitation, nausea, and vomiting (Spagnoli et al., 1991). 
5.3 Propionyl-L-carnitine (PLC) 
PLC is a natural short-chain derivative of L-Car and it has a higher transport rate into the 
myocardium than L-Car (Sayd-Ahmed et al., 2000). 
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5.3.1 Structure of PLC  
PLC is chemically similar to carnitine, but is more efficient (Ferrari et al., 2004). Chemical 
structure of PLC is shown in fig. 3 (molecular formula: C10H19NO4). 
 
 
Fig. 3. Chemical structure of PLC 
5.3.2 Pharmacokinetics of PLC  
PLC is formed via carnitine acetyltransferase from propionyl-CoA, a product of methionine, 
threonine, valine, and isoleucine, as well as of odd-chain fatty acids (Ferrari et al., 2004). 
PLC has higher affinity for the plasma membrane transport system. It is more lipophylic and 
penetrates myocytes faster than L-Car (Lango et al., 2001). Pharmacokinetic studies 
demonstrated that, in humans, plasma concentration of PLC increases following 
intravenous administration and then decreases to baseline values within 6 to 24 h. This life 
span varies with dosage (Ferrari et al., 2004). The plasma concentrations of endogenous PLC 
in placebo-treated subjects averaged 1.28 nanomol/ml, over the 24 h period of observation. 
Intravenous PLC has a short elimination half-life (1 h), a small volume of distribution (18 l) 
and a clearance of about 11 l/h; the renal clearance of PLC increases as the intravenous dose 
of PLC hydrochloride is increased; and, based on urinary excretion data, L-Car is a major 
metabolite of intravenously administered PLC hydrochloride. The corresponding value for 
the estimate of creatinine clearance, which is assumed to be equal to GFR, was 6.08 l/h. 
Because PLC does not bind to plasma proteins, these data indicate extensive tubular 
reabsorption of PLC (about 95%). The renal handling of PLC in humans involves saturable 
tubular reabsorption. The results of in vitro studies have found that PLC is stable to 
hydrolysis in whole blood, but readily undergoes hydrolysis to L-Car on exposure to 
hepatic and renal homogenates. The L-Car formed from PLC was likely to have been 
converted to ALC, resulting in the observed increases in the plasma and urinary levels of the 
acylated product (Pace et al., 2000). 
5.3.3 Mechanism of action of PLC 
PLC is an energy source, and it stimulates the Krebs cycle as a precursor of succinyl-CoA, 
decreases oxidative stress in various systems, and improves cardiac dysfunction in rodent 
models (Vermeulen et al., 2004). It is now generally agreed that I/R injury in the heart is 
associated with accumulation of long chain acylesters. The increase of long chain acylesters 
and depletion of free L-Car in the myocardium have been suggested to damage the cardiac 
cell membrane and impair the electrical and contractile activities of the heart. It has been 
shown that PLC administration improves the recovery of mechanical function of the 
ischemic-reperfused hearts. PLC administration to rats with pressure-overload heart 
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hypertrophy and volume overload heart hypertrophy has been reported to improve cardiac 
function. Furthermore, PLC was found to exert beneficial effects on myocyte performance 
and ventricular dilatation in rats subjected to MI (Sethi et al., 1999). PLC increases plasma 
and cellular carnitine content, thus enhancing FFA oxidation in carnitine-deficient states, as 
well as increasing glucose oxidation rates. During the reperfusion of previously ischemic 
hearts, PLC stimulated glucose oxidation and significantly improved the functional 
recovery. This supported the theory that carnitine’s beneficial effects on ischemic 
myocardium are the result of its ability to overcome the inhibition of glucose oxidation that 
is induced by increased levels of fatty acids (Ferrari et al., 2004). PLC enhances the propionyl 
group uptake by myocardial cells. This is important because propionate can be used by 
mitochondria as an anaplerotic substrate, thus providing energy in the absence of oxygen 
consumption. Note that propionate alone cannot be administered because of its toxicity. 
Because of the particular structure of the molecule with a long lateral tail, PLC has a specific 
pharmacologic action that is independent of its effect on muscle metabolism; this result in 
peripheral dilatation, positive inotropic effects and coronary vasodilatation with reduced 
oxygen extraction. It is clear that typical inotropic agents, such as digitalis, calcium, and 
adrenergic compounds, cause a decline in the phosphocreatinine (PCr)/Pi ratio; this 
suggested that they place the heart in a supply/demand imbalance. This was not the case 
for PLC. Thus, all of the cardiovascular actions of PLC can be attributed to its pharmacologic 
properties rather than to its role as a metabolic intermediate. Energy metabolism remained 
unchanged despite the increase in myocardial performance (Ferrari et al., 2004). It seems 
that PLC improved skeletal muscle metabolism in patients with idiopathic dilated 
cardiomyopathy by increasing pyruvate flux into the Krebs cycle and decreasing lactate 
production. This effect, which occurs in the absence of major hemodynamic and 
neuroendocrine changes, may underlie the ability of PLC to increase exercise performance 
in patients with CHF. It was reported that, when PLC was given to patients with severe 
heart failure (NYHA IV), it was able to reduce the increase in tumor necrosis factor-ǂ (TNF-
ǂ) and, in particular, its soluble receptor that is elevated in CHF, and that is responsible for 
intracellular signaling of the effects of TNFǂ. An increased TNF was implicated in the 
skeletal muscle changes of patients with CHF (Ferrari et al., 2004). Similar to L-Car, PLC 
have also been proposed to alleviate the noxious effects of oxygen free radicals in the 
reperfused hearts and to delineate cardiac cells more resistant to I/R damage by stabilizing 
cellular membranes (Calvani et al., 2000). Endothelial cellular membranes are better 
protected by PLC against Fe2 and Fe3 ions induced peroxide production, the protection 
being possibly due to ion chelating (Lango et al., 2001). Finally, attenuating defects in the 
sarcolemmal membrane may be the other mechanism of PLC and thus may improve heart 
function in CHF due to MI (Sethia et al., 1999). 
5.3.4 Uses of PLC in cardiovascular health and diseases 
PLC has shown efficacy in the treatment of a number of cardiovascular disorders including 
ischemic heart disease, CHF and hypertrophic heart disease. PLC efficacy on cardiac 
performance is greater than that observed with L-Car (Calvani et al., 2000). Because of PLC’s 
characteristics, it was hypothesized that it could provide adjuvant benefit over standard 
therapy by specifically improving impaired metabolism of skeletal and heart muscle in 
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patients with CHF (Ferrari et al., 2004). The effects of PLC in a number of models of CHF are 
particularly evident under conditions of high-energy demand that is induced by increases in 
workload. Therefore, it seems likely that PLC is able to correct some metabolic steps of the 
process that leads to heart failure. Besides its effect on the heart, PLC could be helpful in 
CHF for a specific action on peripheral heart muscle. In CHF, exertional fatigue is not 
simply the result of skeletal muscle under perfusion. In most patients, there is a decrease in 
flow responses to exercise as a result of an abnormality of arterial vasodilatation, evidenced 
by a failure of leg vascular resistances to decrease during exercise. The use of PLC improves 
the walking capacities of patients with peripheral arterial disease, suggested that PLC could 
specifically improve metabolism and function of skeletal muscle in patients with CHF. 
There are several studies on the effects of PLC in peripheral artery disease (Ferrari et al., 
2004). PLC hemodynamic effect was evaluated in patients with CAD with normal LV 
function. When PLC was intravenously administered at 15 mg/kg, it improved the stroke 
volume and reduced the ejection impedance as a result of decreased systemic and 
pulmonary resistances and increased arterial compliance. Total external heart power 
improved with a proportionally smaller increase in the energy requirement; this suggested 
that PLC has a positive inotropic property. PLC increased the performance of the aerobic 
myocardium independent on changes of peripheral hemodynamics or coronary flow when 
administered chronically to the animals several days before the isolation of the heart (Ferrari 
et al., 2004). PLC used in doses of 15 mg/kg caused a slight decrease in peripheral vascular 
resistance in patients with stable coronary disease, but due to a simultaneous increase in 
stroke volume, no decrease in arterial blood pressure was observed. A similar dose 
administered to patients with ischemic heart disease caused in a short time (5 min) a 43% 
increase in lactate uptake by myocardium and increase in stroke volume by 8% (Lango et al., 
2001). The protective effect of PLC in perfused rat hearts is dose-dependent and also 
depends on the time of administration, provided it is administered before post-ischemic 
reperfusion begins. From the accumulated results, it seems that positive biological effects 
observed after PLC are more evident than those after L-Car administration. Better 
penetration into myocytes and supplying a substrate for the citric acid cycle can explain this 
observation in short-term supplementation (Lango et al., 2001). In isolated rat hearts that 
were subjected to global low-flow ischemia, the group that was treated with PLC exhibited 
significantly greater recovery of all hemodynamic variables during reperfusion. In a similar 
preparation, 1 mmol PLC had no protective effect, whereas 5.5 and 11 mmol improved the 
recovery of cardiac output. The beneficial effect is greater than that of L-Car on a molar 
basis. PLC was also found to directly improve postischemic stunning. Specific experimental 
studies were conducted on the efficacy of this agent with respect to CHF. In particular, 
treatment with PLC (50 mg/kg, intra-arterially) for 4 days significantly improved the 
hemodynamics of pressure overloaded (by constriction of the abdominal aorta) in conscious 
rats. In another study, papillary muscles were isolated from rats that had been treated with 
180 mg/kg PLC for 8 weeks, starting from weaning. Aortic constriction was performed at 8 
weeks of age and lasted for 4 weeks. The papillary muscles of untreated animals showed 
increased time-to-peak tension and a reduced peak rate of tension rise and delay. PLC 
normalized all of these parameters. In an infarct model of CHF, chronic administration of 
PLC (60 mg/kg orally given for 5 months) positively influenced ventricular remodeling; it 
was equally as effective as the ACE inhibitor, enalapril (l mg/kg orally), in limiting the 
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magnitude of LV dilatation estimated by pressure-volume curves. PLC limited the 
alterations in ventricular chamber stiffness that was induced by infarction at low and high 
filling pressures. In isolated myocytes obtained from infarcted rats, PLC increased peak 
systolic calcium, peak shortening, and velocity of cell shortening to a greater extent than in 
normal cells (Ferrari et al., 2004). 
5.3.5 Experimental and clinical findings on beneficial effects of PLC against cardiac 
arrhythmias 
The antiarrhythmic effect of PLC was evaluated in the guinea-pig isolated heart; 
arrhythmias were induced with hypoxia followed by reoxygenation and by digitalis 
intoxication. PLC 1 µm, was found to be the minimal but effective antiarrhythmic 
concentration against reoxygenation-induced VF. The antiarrhythmic action of L-PC on 
reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological 
effects studied on normoxic preparations. No antiarrhythmic effect was observed against 
digitalis induced arrhythmias. D-Propionyl carnitine and propionic acid did not exert 
antiarrhythmic effects. During hypoxia and reoxygenation, PLC consistently prevented the 
rise of the diastolic left ventricular pressure, and significantly reduced the release of the 
cardiac enzymes creatine kinase (CK) and lactic dehydrogenase (LDH) (Barbieri et al., 1991). 
5.3.6 Uses of PLC in other human diseases 
5.3.6.1 Cisplatin induced nephrotoxicity 
It is well known that Cisplatin induced nephrotoxicity is the most important dose-limiting 
factor in cancer chemotherapy. Cisplatin therapy is usually associated with cardiotoxicity 
including electrocardiographic changes, arrhythmias, myocarditis, cardiomyopathy and 
congestive heart failure. Combinations of Cisplatin with other anticancer drugs as 
methotrexate, 5-fluorouracil, bleomycin and doxorubicin are associated with lethal 
cardiomyopathy. PLC has potential protective effect against Cisplatin-induced cardiac 
damage with no interfere with the antitumor activity of anticancer drugs. PLC mechanism 
of action in this case may be due to membrane stabilization by the L-Car portion of PLC 
with the consequent decrease in release of cardiac enzymes or due to its antioxidant activity 
(Al-Majed et al., 2006). 
5.3.6.2 Sickle-cell anemia 
Sickle-cell anemia erythrocytes are under oxidative stress which contributes to some 
modifications observed in these cells. PLC by antioxidant activity is able to stabilize 
damaged cell membranes and is also able to decrease the formation of thiobarbituric acid 
reactive substances. Thus it may be beneficial in maintaining the normal shape of sickle-cell 
anemia erythrocytes at low oxygen tension and in decreasing the peroxidative damages 
which accumulate during the life of red blood cells (Ronca et al., 1994). 
5.3.6.3 Peripheral arterial disease  
PLC stimulates energy production in ischemic muscles by increasing citric acid cycle flux 
and stimulating pyruvate dehydrogenase activity. Also PLC improves coagulative 
fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. 
Improvements in maximum walking distance (MWD) correlated positively with increased 
mitochondrial oxidative ATP synthesis in patients with intermittent claudication. Oral PLC 
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therapy was associated with significant improvements in quality of life in patients with a 
baseline MWD < 250m (Wiseman et al., 1998). In comparison with pentoxifyllin, PLC had 
the better effect in the treatment of critical ischemia (Milio et al., 2009; Signorelli et al., 2001). 
In patient with Leriche-Fontaine stage II peripheral arterial disease of lower limbs LPC 
showed improvement on circulatory reserve of the ischemic limb without any effect on 
heart rate and arterial blood pressure. The effect of LPC on the hyperemic response to stress, 
mainly on halftime of hyperemia, was possibly due to a drug-induced increase of ATP 
utilization by the ischemic tissues (Corsi et al., 1995).  
5.3.6.4 Chronic fatigue syndrome 
The symptoms of chronic fatigue syndrome by treatment of PLC showed considerable 
improvement in 63% of the patients (Vermeulen et al. 2004). 
5.3.7 Adverse effects of PLC 
PLC may cause some transient and mild gastrointestinal side effects. These adverse effects 
include nausea, vomiting, abdominal pain, cramps and diarrhea. PLC also may cause 
seizures in susceptible individuals because of its close structural resemblance to L-Car. Some 
patients with pre-existing seizure disorders have reported an increase in the number or 
frequency of seizures upon using PLC. A study mentions that L-Car, a chemical component 
of PLC, is a peripheral antagonist of the action of thyroid hormones on the body. This means 
that the circulating L-Car in the blood opposes the action of the thyroid hormones at their 
site of action. For patients suffering from decreased thyroid function, this could aggravate 
their condition. PLC could cause other rare side effects such as a body odor, fishy smell of 
urine and stool and increased appetite. Such adverse effects are more common upon 
administration of doses as high as 3 grams of PLC. Decreasing the dose usually eliminates 
these untoward side effects (Nnama, 2010). 
5.4 Ranolazine 
5.4.1 Structure of ranolazine 
Ranolazine is a substituted piperazine compound similar to Trimetazidine (Morin et al., 
2001). It is a racemic mixture and chemically described as 1-piperazine acetamide, N-(2, 6-
dimethyl phenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy) propyl]. Its empirical formula is 
C24H33N3O4 with following chemical structure (Bhandari & Subramanian, 2007): 
 
Fig. 4. Chemical structure of ranolazine. 
5.4.2 Pharmacokinetics of ranolazine 
Peak plasma concentrations (Cmax) are observed within 4-6 hours of administration with 
extended-release tablets. In case of oral solution or immediate release (IR) capsule, Cmax is 
achieved in an hour. After administration of radiolabelled ranolazine, 73% of administered 
www.intechopen.com
 
Metabolic Modulators to Treat Cardiac Arrhythmias Induced by Ischemia and Reperfusion 
 
141 
dose was excreted in urine with <5% excreted unchanged in both urine and feces. 
Bioavailability of ranolazine is 35-50% and food does not interfere with its absorption. It is 
primarily metabolized by cytochrome P450 (CYP) 3A enzyme. Pharmacokinetics of 
ranolazine is not affected by sex, but existence of marked gender difference in ranolazine 
pharmacokinetics in rats has been demonstrated. Pharmacokinetics is unaffected in the 
presence of concomitant illnesses like CHF and diabetes mellitus. Dose adjustments are 
required in renal failure (Bhandari & Subramanian, 2007). 
5.4.3 Mechanism of action of ranolazine 
Ranolazine is a partial fatty acid oxidation (pFOX) inhibitor that directly inhibits fatty acid 
ǃ-oxidation and thus reduces inhibition of PDH by fatty acid oxidation (Sabbah & Stanley, 
2002). This metabolic switch increases ATP production per mole of oxygen consumed, 
reduces the rise in lactic acid and acidosis, and maintains myocardial function under 
conditions of reduced myocardial oxygen delivery. This mechanism of action of ranolazine 
may explain its antiischaemic action, in the absence of any hemodynamic effects (without 
reduction of heart rate or blood pressure or increases of coronary blood flow) in human and 
animal models (Zacharowski et al., 2001; Cairns, 2006). In addition, blockade of a late 
sodium current that facilitates calcium entry may play a role in the action of ranolazine 
(Hume & Grant, 2007). Reducing reactive oxygen species (ROS) concentration by decreasing 
lipid oxidation could be another possible mechanism of action of ranolazine (Bhandari & 
Subramanian, 2007). 
5.4.4 Experimental and clinical findings on beneficial effects of ranolazine in 
cardiovascular diseases 
Ranolazine has shown cardiac antiischemic and antianginal activity in several in vitro and in 
vivo animal models and clinical trials (Morin et al., 2001). Results of a study demonstrated 
that ranolazine behaves as a weak ǃ1- and ǃ2-adrenoceptor antagonist in the rat 
cardiovascular system (Létienne et al., 2001). In dogs with experimentally-induced heart 
failure, acute intravenous administration of ranolazine, improved LV ejection fraction as 
well as other indexes of LV performance. In contrast, ranolazine had no effect on LV 
function in normal dogs, suggesting that this agent was devoid of any classical cAMP-
mediated positive inotropic effects. Ranolazine also improved LV systolic function without 
increasing coronary blood flow or myocardial oxygen consumption. These studies suggest 
that pharmacologically switching the oxidative fuel of the heart away from fatty acids 
towards carbohydrate can improve mechanical efficiency of the failing heart (Sabbah et al., 
2002). Previously, we demonstrated that ranolazine reduced number and incidence of VT 
and the time spent for reversible VF in the ischemic-reperfused isolated rat heart (Najafi & 
Eteraf Oskouei, 2007). Dhalla et al. tested the effect of ranolazine on ventricular arrhythmias 
in an ischemic model using two protocols. In protocol 1, anesthetized rats received either 
vehicle or ranolazine (10 mg/kg, iv bolus) and were subjected to 5 min of LAD occlusion 
and 5 min of reperfusion with electrocardiogram and blood pressure monitoring. In 
protocol 2, rats received either vehicle or three doses of ranolazine (iv bolus followed by 
infusion) and 20 min of LAD occlusion. With both protocols, occurrence and duration of VT 
and incidence of VF significantly reduced in ranolazine-treated rats. Ranolazine also reduces 
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experimental ST segment elevation and myocardial infarct size and enhances function of 
stunned myocardium in the peri-infarct area (Dhalla et al., 2009). In isolated canine 
ventricular myocytes and arterially perfused left ventricular function, ranolazine have 
shown to produce antiarrhythmic activity along with antianginal actions. Ranolazine 
produces ion channel effects similar to those observed after chronic exposure to 
amiodarone. Although ranolazine have shown to cause modest prolongation of the QT 
interval and action potential duration, but this prolongation is not associated with early 
after depolarization, triggered activity or polymorphic ventricular activity. Torsades de 
pointes arrythmias were not observed spontaneously and even on stimulation at 
concentration as high as 100 micromol/L. Rather, ranolazine is found to possess significant 
antiarrhythmic activity and suppress the arrhythmogenic effects of other QT-prolonging 
drugs (Bhandari & Subramanian, 2007). After several clinical trials, ranolazine was 
approved in the United States and Europe for the treatment of chronic angina pectoris 
(Dhalla et al., 2009). Because ranolazine prolongs the QTc, the FDA approval is limited to 
patients who have not responded to other antianginal drugs, and its use in combination 
with amlodipine, beta-blockers, or long-acting nitrates is recommended. The daily dose 
should be limited to 1,000 mg and precautions are advised regarding QTc prolongation 
(Cairns, 2006). Clinical trials also demonstrate the ability of ranolazine to decrease the 
incidence of VT, supraventricular tachycardia, and ventricular pauses. These antiarrhythmic 
effects likely arise from the ability of ranolazine to inhibit the late Na+ current. The 
antiischemic and antiarrhythmic effects of ranolazine are not mutually exclusive, as they 
occur at similar concentrations (Lopaschuk et al., 2010). Non-insulin-dependent diabetes 
mellitus is characterized by elevated fatty acids (FA) levels due to diminished action of 
insulin in inhibiting FA release from adipocytes. FA may contribute to hyperglycemia by 
stimulating gluconeogenesis in the liver in the post absorptive state. It also attenuates 
glucose disposal in skeletal muscle in the fed state. FA oxidation inhibitors may be helpful 
in controlling hyperglycemia by reducing glucose production in humans. Protective role of 
the metabolic agents in diabetes with ischemic cardiomyopathy with trimetazidine have 
been demonstrated. However, the potential usefulness of ranolazine in diabetic patients is 
expected, but clinical trials are still awaited (Bhandari & Subramanian, 2007). 
5.4.5 Adverse effects of ranolazine 
The most common adverse effects are dizziness, nausea, asthenia and constipation. Postural 
hypotension, syncope, headache, dyspepsia and abdominal pain are also reported. 
Ranolazine should not be administered along with CYP3A inhibitors like ketoconazole, 
verapamil, diltiazem etc. Ranolazine itself is a weak inhibitor of CYP3A and increases Cmax 
for simvastatin. By inhibiting P-glycoprotein, it increases plasma concentration of digoxin. 
Ranolazine should be avoided in liver disease, hypokalemia, or if there is a personal or 
family history of Long QT syndrome (Bhandari & Subramanian, 2007). 
5.5 Trimetazidine 
Trimetazidine is likely to stimulate carbohydrate oxidation by directly inhibiting the ǃ-
oxidation of fatty acids and secondarily activating PDH (Hara et al., 1999). 
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5.5.1 Structure of trimetazidine 
Trimetazidine [(1-(2,3,4-trimethoxy-benzyl)-piperazine dihydrochloride] with molecular 
formula: C14H22N2O3 (Fig. 5) is a well-established drug which has been extensively used 
since 1961 in the treatment of ischemia in angina pectoris and during heart surgery (Tanaka 
et al., 2005; Ancerewicz et al., 1998). 
 
 
Fig. 5. Chemical structure of trimetazidine. 
5.5.2 Pharmacokinetics of trimetazidine 
Trimetazidine is absorbed through the intestinal mucosa with a Tmax of 5.4 hours. The 
Cmax is 89 microgram/L. The bioavailability is 87%, slightly inferior with trimetazidine 
modified release than with the immediate-release formulation, explaining the increase in the 
dose of trimetazidine. The bioavailability is not influenced by food. The steady state is 
reached 2 to 3 days after starting the treatment. The volume of distribution, unaffected by 
the modified-release formulation, is 4.8 L/kg which means good tissue diffusion. Protein 
binding affinity is low (16%), with equal binding to albumin and alpha-glycoprotein. No 
uptake of trimetazidine in red blood cells was observed. The major drug related component 
observed in plasma and urine was unchanged trimetazidine. In addition to the parent drug, 
10 metabolites were detected in urine. Seven routes of metabolism have been identified in 
man: 2 phase I oxidation and 5 phase II conjugation routes. Trimetazidine and its 
metabolites are predominantly eliminated in urine. A small proportion of trimetazidine is 
excreted in the faeces (about 6% of the administered dose). The renal trimetazidine clearance 
is 350 ml/min and is independent of the urine and plasma concentration of the drug, 
whereas it is correlated with renal creatinine clearance. That is why the elimination half-life 
is shorter in the healthy patients as compared with the elderly patients (7 and 12 hours, 
respectively). Trimetazidine can be safely prescribed without adapting the dose in elderly 
patients and in case of renal insufficiency (if creatinine clearance remains above 15 ml/min) 
(http://www.cipladoc.com/therapeutic/pdf_cipla/trivedon_mr.pdf). 
5.5.3 Mechanism of action of trimetazidine 
Trimetazidine has been shown in numerous trials to be a moderately effective prophylactic 
antianginal agent. The exact mechanism of antiischemic effect of trimetazidine remains 
controversial, but its efficacy cannot be accounted for on the basis of purely hemodynamic 
changes (Horowitz et al., 2010). Trimetazidine has no negative inotropic or vasodilator 
properties. It is thought to have direct cytoprotective actions on the myocardium (Kantor et 
al., 2000). The experimental finding that trimetazidine inhibits the enzyme long-chain 3-
ketoacyl-CoA thiolase (3-KAT) has led to its being categorized as a partial fatty acid 
oxidation inhibitor (Horowitz et al., 2010) and a stimulation of glucose oxidation (Kantor et 
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al., 2000). Recent clinical studies have supported this suggestion, demonstrating that 
trimetazidine inhibits myocardial fatty acid oxidation and augments glucose utilization. 
Importantly, trimetazidine is also free of the potential to induce tissue phospholipids 
accumulation with associated toxicity (Horowitz et al., 2010). The relatively low potency of 
trimetazidine as a carnitine palmitoyltransferase-1 inhibitor makes the mechanism of 
inhibiting of long-chain fatty acid oxidation and increasing myocardial oxygen utilization, 
and explains its therapeutic antiischemic effect (Kennedy et al., 1998). Trimetazidine is 
clinically utilized as an antianginal therapy throughout Europe and in over 90 countries. By 
inhibiting fatty acid ǃ-oxidation, trimetazidine causes a reciprocal increase in glucose 
oxidation, thereby decreasing the production of H+ arising from glycolysis uncoupled from 
glucose oxidation. Interestingly, in the setting of pressure-overload cardiac hypertrophy, 
where the rates of fatty acid ǃ-oxidation are depressed, trimetazidine confers 
cardioprotection independently of alterations in fatty acid ǃ-oxidation. Rather, trimetazidine 
attenuates the elevated rates of glycolysis and increases glucose oxidation to limit the 
production of H+ attributed to glucose metabolism. The inhibition of glycolysis coupled 
with the increase in glucose oxidation, or the partial inhibition of fatty acid ǃ–oxidation and 
the parallel stimulation of glucose oxidation, can limit ischemia-induced disturbances in 
myocardial ionic homeostasis. Specifically, the improved coupling of glucose metabolism 
attenuates intracellular acidosis as well as Na+ and Ca2+ overload during ischemia and 
subsequent reperfusion and improves the recovery of post ischemic cardiac function. 
Trimetazidine also affects on cardiac myocyte Ca2+ handling that can limit ischemic 
myocardial injury, including reductions in Ca2+ current, prevention of elevated[Ca2+]i, and 
preservation of SR Ca2+-ATPase activity that may limit or prevent cytosolic Ca2+ overload. 
Therefore, the metabolic effects of trimetazidine are permissive to increasing cardiac 
efficiency by sparing ATP hydrolysis from being utilized to correct ionic homeostasis, and 
making it available to fuel contractile work (Lopaschuk et al., 2010). Trimetazidine also 
enters brain tissues in low concentrations. Since oxygenated free radicals are believed to 
play a major role in both I/R injury and neurodegenerative diseases (Alzheimer and 
Parkinson’s disease), it was suggested that trimetazidine might possess antioxidant 
properties (Ancerewicz et al., 1998).  
5.5.4 Experimental and clinical findings on beneficial effects of trimetazidine in 
cardiovascular diseases 
Trimetazidine is efficacious in the treatment of angina, MI and heart failure. The 
antiischemic effects of trimetazidine in the treatment of angina include an increased time to 
1-mm ST segment depression and decreased weekly nitrate consumption disease 
(Lopaschuk et al., 2010). Trimetazidine has also been shown to significantly improve 
exercise-induced anginal symptoms in patients with CAD without eliciting any of the classic 
antiischemic effects of traditional therapies such as a decrease in heart rate, coronary 
vasodilation, or a decrease in arterial blood pressure (Sabbah & Stanley, 2002). In acute MI, 
the cardioprotective effects of trimetazidine are evident as a reduction in reperfusion 
arrhythmias and a more rapid resolution of ST segment elevation. The addition of 
trimetazidine to treatment regimens also improves NYHA functional class, LV end-diastolic 
volume, and ejection fraction in patient with heart failure and ischemic cardiomyopathy, as 
well as idiopathic dilated cardiomyopathy. Thus, the partial inhibition of fatty acid ǃ-
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oxidation, via the reversible, competitive inhibition of 3-KAT attenuates several 
consequences of various forms of ischemic heart disease (Lopaschuk et al., 2010). It was 
reported that trimetazidine therapy was associated with QTc interval shortening in patients 
with ischemic heart failure (Zemljic et al., 2010). In the ischemic cardiomyopathy, despite 
treatment with conventional agents, a high proportion of patients continue to have 
symptoms and a substantial proportion shows progressive contractile dysfunction leading 
to LV enlargement and heart failure. Thus, there is a need for new treatments for ischemic 
cardiomyopathy that apply mechanisms other than those already addressed by 
conventional agents. There are many evidences suggesting that in patients with ischemic 
cardiomyopathy, LV dysfunction progress in consequence of alterations in substrate 
metabolism. Trimetazidine, which acts on myocardial metabolic pathways, appears to 
protect the heart from the deleterious effects of ischemia, and it has been shown to enhance 
LV contractility in patients with stunned or hibernating myocardium. Trimetazidine has 
been shown to improve symptoms and LV ejection fraction and to have a beneficial effect on 
the inflammatory profile and endothelial function in these patients. These results suggest 
that trimetazidine is a useful adjunct to the current treatments for the patients with ischemic 
cardiomyopathy (Bertomeu-Gonzalez et al., 2006). Muscle's metabolic and vascular effects of 
trimetazidine add new interest in the use of trimetazidine in type 2 diabetic patients with 
ischemic cardiomyopathy (Monti et al., 2006). It has shown improvement in LV function, 
symptoms, glucose metabolism and endothelial function in such patients (Bhandari & 
Subramanian, 2007). Despite beneficial uses, trimetazidine can induce some adverse effects 
including parkinsonism, gait disorder and tremor (Martí Massó et al., 2005).  
5.6 Etomoxir 
5.6.1 Structure of etomoxir 
Etomoxir {2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate} is an irreversible inhibitor of 
carnitine palmitoyl transferase I (CPT-I) that was initially introduced as a potential anti-
diabetic agent based on its hypoglycemic effects (Lee et al., 2004, Lopaschuk et al. 2010). 
 
 
Fig. 6. Chemical structure of etomoxir. 
5.6.2 Mechanism of action of etomoxir 
Etomoxir inhibits CPT-I, the key enzyme involved in fatty acid uptake by the mitochondria 
(Baetz et al., 2003), and alters the balance between myocardial fatty acid ǃ-oxidation and 
glucose oxidation. It leads to reduced fatty oxidation rates, increased glucose oxidation rates 
and improved myocardial energy efficiency. Although etomoxir has been investigated as a 
treatment for heart failure, it has not yet been studied as an antianginal agent (Lam A & 
Lopaschuk, 2007).  
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5.6.3 Experimental and clinical findings on beneficial effects of etomoxir in 
cardiovascular diseases  
In experimental models of I/R, etomoxir improves the recovery of ventricular function 
following ischemia. In palmitate-perfused ischemic rat hearts, etomoxir reduced oxygen 
consumption during ischemic recovery and also prevented depression of myocardial 
function. In pressure-overloaded, hypertrophic, and failing rat hearts, etomoxir led to an 
improvement in indices of left ventricular dysfunction (Lee et al., 2004). In isolated rat 
hearts, perfusion of etomoxir-enriched K/H solution significantly decreased the incidence of 
ischemic VT and the time spent for reversible VF (Najafi & Eteraf Oskouei, 2007). This 
cardioprotective effect is also afforded to the postischemic diabetic heart and may suggest 
the possible clinical utility of etomoxir in patients with diabetic cardiomyopathy. The 
protective effects of etomoxir in the postischemic period are accompanied by increased rates 
of myocardial glucose oxidation and an increased production and utilization of ATP for 
contractile work due to the stimulation of the cardiac PDH complex (via the Randle cycle). 
Although clinical experience with etomoxir is very limited, its potential beneficial effects on 
heart function have been assessed in a small (15 patients) uncontrolled, open-label study of 
patients with NYHA class II heart failure. Following 3 months of etomoxir treatment (80 
mg), there was an improvement in LV ejection fraction, cardiac output at peak exercise, and 
clinical status; however, this trial was not able to assess the long-term safety of etomoxir 
treatment. More recently, etomoxir for the recovery of glucose oxidation (ERGO) study had 
to be stopped early as several patients with NYHA class II-class III heart failure in the 
treatment group were found to have elevated liver transaminase enzyme levels. This 
adverse effect may be related to the irreversible inhibition of CPT-1 in response to etomoxir, 
an effect that may allow toxicity to manifest from its excessive accumulation. This study did 
not detect any significant improvement in the etomoxir group (40 and 80 mg) as compared 
with placebo (likely due to limited power); however, there was a trend to increased exercise 
time (Lopaschuk et al. 2010). 
5.7 Dichloroacetate (DCA) 
DCA is a PDH activator (Liu et al., 2002) and stimulates carbohydrate oxidation through 
direct inhibition of PDH kinase and reduces fatty acid oxidation through inhibition of fatty 
acid uptake by mitochondria (Hara et al., 1999). 
5.7.1 Structure of DCA 
DCA is a compound with formula CHCl2COOH and below chemical structure (Fig. 7). 
(http://en.wikipedia.org/wiki/Dichloroacetic_acid). 
 
Fig. 7. Chemical structure of DCA. 
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5.7.2 Pharmacokinetics of DCA 
DCA is completely absorbed following oral dosing and about 20% is bound to human 
plasma proteins. In all species examined, the first dose is cleared from plasma more rapidly 
than subsequent doses, although the mechanism for this effect is unknown. Glyoxylate is an 
intermediate in DCA metabolism, and oxalate and CO2 are terminal end products. Neither 
glyoxylate nor oxalate stimulates PDC activity. However, because the actions of DCA in 
humans often persist for several days after its clearance from plasma, it is possible that other 
reactive intermediates of DCA accumulate intracellularly at active sites and bind covalently 
to target proteins, or that DCA (or a metabolite) induces enzymes responsible for its 
pharmacodynamic effects. DCA is excreted with little of the dose unchanged (Stacpoole et 
al., 1998). 
5.7.3 Mechanism of action of DCA 
DCA exerts multiple effects on pathways of intermediary metabolism. It stimulates 
peripheral glucose utilization and inhibits gluconeogeneis, thereby reducing hyperglycemia 
in individuals with diabetes mellitus. It decreases circulating lipid and lipoprotein levels by 
inhibing lipogenesis and cholesterolgenesis, in patients with disorders of lipoprotein 
metabolism. DCA facilitates oxidation of lactate and decreases morbidity in lactic acidosis 
by stimulating the activity of PDH. The drug improves cardiac output and LV mechanical 
efficiency under conditions of myocardial ischemia or failure, probably by accelerating 
myocardial metabolism of carbohydrate and lactate as opposed to fat (Stacpoole, 1989). 
DCA promotes myocardial glucose oxidation at the expense of myocardial fatty acid ǃ-
oxidation; however, unlike trimetazidine and ranolazine, DCA stimulates the mitochondrial 
PDH complex by directly inhibiting the activity of PDH kinase. Experimental studies have 
demonstrated the ability of DCA to enhance the postischemic recovery of cardiac function in 
vitro as well as in vivo. An increase in cardiac efficiency, and an improved coupling 
between glycolysis and glucose oxidation, accompany the cardioprotective effects of DCA 
(Lopaschuk et al., 2010). DCA may also increase regional lactate removal and restoration of 
brain function in the cerebral ischemia. DCA appears to inhibit its own metabolism, which 
may increase the duration of its pharmacologic actions and lead to toxicity. DCA can cause a 
reversible peripheral neuropathy that may be related to thiamine deficiency and may be 
ameliorated or prevented with thiamine supplementation. Despite its potential toxicity and 
limited clinical experience, DCA and its derivatives may be useful in the acute or chronic 
treatment of several metabolic disorders (Stacpoole, 1989). 
5.7.4 Experimental and clinical findings on beneficial effects uses of DCA in 
cardiovascular diseases 
When myocardial carbohydrate oxidation is acutely increased in heart failure patients by 
activating PDH with intravenous DCA, there is a rapid improvement in LV performance 
(Sabbah & Stanley, 2002). Clinical experience with DCA is limited; however, in a small 
clinical trial, DCA increased LV stroke volume and myocardial efficiency, effects 
accompanied by increased lactate utilization. As the metabolic effects of DCA are similar to 
those of trimetazidine and ranolazine, it may be relevant in the therapeutic management of 
angina pectoris; however, its antiischemic efficacy has yet to be established in such a setting 
(Lopaschuk et al., 2010).  
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5.8 Perhexiline 
Perhexiline has similar metabolic and antianginal effects which are found with inhibition of 
CPT-I using such as ranolazine (Sabbah & Stanley, 2002). 
5.8.1 Structure of perhexiline 
Perhexiline is 3 2-(2,2-dicyclohexylethyl) piperidine (Dawson et al., 1986) with following 
structure (Fig. 8). 
 
Fig. 8. The chemical structure of perhexiline (http://en.wikipedia.org/wiki/Perhexiline). 
5.8.2 Pharmacokinetics of perhexiline 
Perhexiline has only ever been available as an oral formulation, thus its bioavailability is 
unknown. However, it has been reported that in a small group of volunteers receiving 400 
mg of perhexiline daily for 14 days, 24 h recoveries of unchanged perhexiline in faeces on 
days 12, 13 or 14 averaged 7.7% (range 0–32.5%), suggesting good absorption from the 
gastrointestinal tract. The major determinant of perhexiline clearance appears to be hepatic 
metabolism, since in humans only approximately 0.1% of a dose is eliminated as unchanged 
drug in urine. Perhexiline forms two primary monohydroxy (OH) metabolites, cis-OH-
perhexiline and trans-OH-perhexiline, which can undergo further secondary metabolism to 
dihydroxy metabolites, as well as glucuronide conjugates. Formation of the major primary 
metabolite, cis-OH-perhexiline is catalysed by CYP2D6, and this metabolic pathway is 
thought to give rise to both the saturability and genetic polymorphism in perhexiline 
clearance (Sallustio et al., 2002). 
5.8.3 Mechanism of action of perhexiline 
Although initially designated as a calcium-channel blocker, it has no significant calcium 
channel blocking activity at therapeutic concentrations. Perhexiline is not negatively 
inotropic and does not change systemic vascular resistance within therapeutic 
concentrations and it is well tolerated by patients with combined angina and LV systolic 
dysfunction. It acts by shifting myocardial substrate utilization from fatty acids to 
carbohydrates through inhibition of CPT-1 following in increased glucose and lactate 
utilization (Lee et al., 2004). It seems that, inhibition of CPT-1 then decreasing fatty acid ǃ-
oxidation is an effective therapeutic approach in various types of ischemic heart diseases 
(Lopaschuk et al., 2010). 
5.8.4 Experimental and clinical findings on beneficial effects uses of perhexiline in 
cardiovascular diseases 
Perhexiline was developed as a prophylactic antianginal agent approximately 40 years ago. 
It was initially thought to be a coronary vasodilator, although in fact its vasomotor effects 
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are minimal – later its weak L-type calcium channel blocking effects were thought to 
underlie its effects. This was inherently implausible, because the observed antianginal 
effects of perhexiline were extraordinary, with relief of otherwise intractable symptoms in 
many patients. Despite its antianginal efficacy, perhexiline induced substantial toxicity, 
which caused a decline in its therapeutic uses from 1980. It was shown that the toxicity of 
perhexiline was preventable, and that the toxicity were observed in patients in whom 
plasma perhexiline levels were elevated beyond 600 µg/ml whereas dosage titration to 
achieve steady-state levels between 150 and 600 µg/ml, serious toxicity was turned away. 
These findings have permitted a reevaluation of the therapeutic role of perhexiline in severe 
angina, and an extension to possible therapeutics of other conditions such as heart failure 
and inoperable aortic stenosis (Horowitz et al., 2010). Of importance is the fact that the 
hepatic toxicity of perhexeline is due to the inhibition of the hepatic isoform of CPT 1. In 
vitro studies clearly demonstrate that the cardiac isoform of CPT 1 is more sensitive to 
inhibition by perhexeline, an effect that allows for the use of dose titration to avoid or limit 
adverse effects. Several clinical trials have demonstrated the beneficial effects of perhexeline 
in aortic stenosis, heart failure, and angina pectoris (Lopaschuk et al., 2010). 
5.8.5 Adverse effects of perhexiline 
Long-term therapy with perhexiline frequently induced both hepatotoxicity and 
neurotoxicity by phospholipidosis in hepatocytes and Schwann cells with this agent. Other 
side effects are nausea, dizziness or both, and hypoglycemia in diabetics. These effects were 
later demonstrated to occur most commonly in patients who are slow hydroxylators, bearers 
of a genetic variant of the cytochrome P-450 enzyme family. These patients are slow 
metabolisers of perhexiline due to saturation of hepatic metabolic pathways, which leads to 
accumulation of the drug and toxicity. The mechanism for toxicity appears to be due to 
phospholipids accumulation, which is a direct consequence of CPT-1 inhibition. Hence, this 
is a potential side effect of any drug that inhibits CPT-1, including amiodarone, which 
exhibits weak CPT-1-inhibitor properties. This is thought to be the mechanism responsible 
for the peripheral neuropathy and hepatitis occasionally seen with amiodarone use (Lee et 
al., 2004). 
6. Conclusion 
Alterations in fatty acid ǃ-oxidation have important implications on cardiac function in both 
heart failure and IHD. Of importance is that emerging evidence suggests that inhibition of 
fatty acid ǃ-oxidation may be a useful approach to improve heart function in the setting of 
obesity, diabetes, heart failure, and IHD. Metabolic agents modulate fatty acid and glucose 
utilization by the myocardium during I/R to protect the heart from I/R injuries such as 
arrhythmias. Some of the agents have well-documented antiischemic and antiarrhythmic 
effects against I/R-induced cardiac arrhythmias.  
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